---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-039338"
form_type: "8-K"
ticker: "CRNX"
cik: "0001658247"
company_name: "Crinetics Pharmaceuticals, Inc."
filed_at: "2023-08-08T23:59:59+00:00"
generated_at: "2026-06-12T02:13:50.311305+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Crinetics Q2 net loss $51M; suspends CRN04777; paltusotine Phase 3 data due Sept 2023

## Summary
- Net loss $51.0M on revenue $1.0M (vs. $42.4M loss on $0.4M revenue in Q2 2022).
- Cash, equivalents, investments $264.5M as of June 30, 2023 (down from $334.4M at Dec 31, 2022).
- Phase 3 PATHFNDR-1 paltusotine topline data expected September 2023; PATHFNDR-2 enrollment complete, data in Q1 2024.
- CRN04777 development suspended after nonclinical findings eroded anticipated therapeutic margins; not related to other candidates.
- Paltusotine NDA submission anticipated in 2024 pending successful PATHFNDR data.

## SEC filing metadata
- accession: 0000950170-23-039338
- form_type: 8-K
- ticker: CRNX
- cik: 0001658247
- company_name: Crinetics Pharmaceuticals, Inc.
- filed_at: 2023-08-08T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1658247/000095017023039338/0000950170-23-039338-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1658247/000095017023039338/crnx-20230808.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-039338
- JSON: https://secwatch.observer/filing/0000950170-23-039338.json
- Plain text: https://secwatch.observer/filing/0000950170-23-039338.txt

## Key facts
- Earnings Releases
  Crinetics Pharmaceuticals, Inc. reported the second quarter ended June 30, 2023 results: revenue $1.0 million, net income Net loss of $51.0 million.
  - Period: the second quarter ended June 30, 2023
  - Revenue: $1.0 million
  - Net income: Net loss of $51.0 million
  - Result: reported results
  source text: of $2.7 million. • Net loss for the three months ended June 30, 2023, was $51.0 million, compared to a net loss of $42.4 million for the same period in 2022. • Revenues were $1.0 million for the three months ended June 30, 2023, compared to $0.4 million for the same period in 2022. Revenues in both periods were primarily derived from the paltusotine licensing
  evidence_url: https://www.sec.gov/Archives/edgar/data/1658247/000095017023039338/0000950170-23-039338-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.